Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2535-2546

  Cosco, Donato ^a   Rocco, Flavio ^b   Ceruti, Maurizio ^b   Vono, Margherita ^a   Fresta, Massimo ^a,c   Paolino, Donatella ^a,c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Campus Universitario 'S Venuta'   (Italy)

Author keywords

Antitumoral nanomedicine; Biodistribution; Leukemia; Nanoaggregate; Self assembly; Squalenoyl cytarabine

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; SQUALENOYL CYTARABINE CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL STRAIN K 562; CELL STRAIN MCF 7; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA L 1210; METASTASIS; MOUSE; NANOFABRICATION; NANOMEDICINE; NONHUMAN; PHYSICAL CHEMISTRY; PRECIPITATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CYTARABINE; HUMANS; LEUKEMIA; LIVER; MICE; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; SPLEEN; SQUALENE; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ARA; MUS;

EID: 84870338004     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S28114     Document Type: Article

References (35)

1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154-1163.
2. Tsurumi H, Kanemura N, Hara T, et al. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol. 2007;133(8):547-553.
3. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther. 2009;31(Pt 2):2349-2370.
4. Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res. 2002;26(7):621-629.
5. Boleti H, Coe IR, Baldwin SA, Young JD, Cass CE. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology. 1997;36(9):1167-1179.
6. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol. 1999;104(2):328-335.
7. Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet. 2002;41(10): 705-718.
8. Celano M, Schenone S, Cosco D, et al. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr Relat Cancer. 2008;15(2):499-510.
9. Paolino D, Cosco D, Licciardi M, Giammona G, Fresta M, Cavallaro G. Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs. Biomacromolecules. 2008;9(4):1117-1130.
10. Fontana G, Maniscalco L, Schillaci D, Cavallaro G, Giammona G. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv. 2005;12(6):385-392.
11. Paolino D, Cosco D, Racanicchi L, et al. Gemcitabine-loaded PEGylated unilamellar liposomes vs Gemzar: biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release. 2010;144(2):144-150.
12. Licciardi M, Paolino D, Celia C, Giammona G, Cavallaro G, Fresta M. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs. Biomaterials. 2010;31(28):7340-7354.
13. Benesch M, Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother. 2008;9(2):301-309.
14. Parasole R, Menna G, Marra N, et al. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions. Leuk Lymphoma. 2008;49(8):1553-1559.
15. Benesch M, Siegler N, Hoff K, et al. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs. 2009;20(9):794-799.
16. Reddy LH, Couvreur P. Squalene: A natural triterpene for use in disease management and therapy. Adv Drug Deliv Rev. 2009;61(15): 1412-1426.
17. Newmark HL. Squalene, olive oil, and cancer risk: a review and hypothesis. Cancer Epidemiol Biomarkers Prev. 1997;6(12):1101-1103.
18. Smith TJ. Squalene: potential chemopreventive agent. Expert Opin Investig Drugs. 2000;9(8):1841-1848.
19. Couvreur P, Reddy LH, Mangenot S, et al. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small. 2008;4(2):247-253.
20. Couvreur P, Stella B, Reddy LH, et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 2006;6(11):2544-2548.
21. Castelli F, Sarpietro MG, Ceruti M, Rocco F, Cattel L. Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. Mol Pharm. 2006;3(6): 737-744.
22. Sarpietro MG, Micieli D, Rocco F, Ceruti M, Castelli F. Conjugation of squalene to acyclovir improves the affinity for biomembrane models. Int J Pharm. 2009;382(1-2):73-79.
23. Voyron S, Rocco F, Ceruti M, et al. Antifungal activity of bisazasqualenes, inhibitors of oxidosqualene cyclase. Mycoses. 2010;53(6): 481-487.
24. Ceruti M, Balliano G, Rocco F, et al. Synthesis and biological activity of new iodoacetamide derivatives on mutants of squalene-hopene cyclase. Lipids. 2005;40(7):729-735.
25. Bergman AM, Pinedo HM, Jongsma AP, et al. Decreased resistance to gemcitabine (2t,2,-difluorodeoxycitidine) of cytosine arabinosideresistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol. 1999;57(4):397-406.
26. Mudhakir D, Akita H, Khalil IA, Futaki S, Harashima H. Pharmacokinetic analysis of the tissue distribution of octa-arginine modified liposomes in mice. Drug Metab Pharmacokinet. 2005;20(4):275-281.
27. Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 1990;50(19):6371-6378.
28. Bildstein L, Dubernet C, Marsaud V, et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. J Control Release. 2010;147(2):163-170.
29. Reddy LH, Khoury H, Paci A, et al. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos. 2008;36(8):1570-1577.
30. Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 2003;22(47):7524-7536.
31. Reddy LH, Dubernet C, Mouelhi SL, Marque PE, Desmaele D, Couvreur P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release. 2007;124(1-2):20-27.
32. Reddy LH, Renoir JM, Marsaud V, Lepetre-Mouelhi S, Desmaële D, Couvreur P. Anticancer eff icacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol Pharm. 2009;6(5):1526-1535.
33. Reddy LH, Marque PE, Dubernet C, Mouelhi SL, Desmaële D, Couvreur P. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther. 2008;325(2):484-490.
34. Wanko SO, de Castro C. Hairy cell leukemia: an elusive but treatable disease. Oncologist. 2006;11(7):780-789.
35. Strandberg TE, Tilvis RS, Miettinen TA. Metabolic variables of cholesterol during squalene feeding in humans: comparison with cholestyramine treatment. J Lipid Res. 1990;31(9):1637-1643.